What impact could transcutaneous vagal nerve stimulation have on an aging population? by Bretherton, B et al.
This is a repository copy of What impact could transcutaneous vagal nerve stimulation 
have on an aging population?.




Bretherton, B orcid.org/0000-0003-1569-5872, Deuchars, J 
orcid.org/0000-0002-4445-654X and Deuchars, SA orcid.org/0000-0002-1876-3239 (Cover
date: June 2019) What impact could transcutaneous vagal nerve stimulation have on an 
aging population? Bioelectronics in Medicine, 2 (2). pp. 59-61. ISSN 2059-1500 
https://doi.org/10.2217/bem-2019-0022
© 2019, Future Medicine Ltd. This is an author produced version of a journal article 





Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless 
indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by 
national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of 
the full text version. This is indicated by the licence information on the White Rose Research Online record 
for the item. 
Takedown 
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by 
emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request. 
What impact could transcutaneous vagal nerve stimulation have on an aging population? 
 
Beatrice Bretherton, Jim Deuchars, Susan A. Deuchars. 
 
School of Biomedical Sciences, Faculty of Biological Sciences, University of Leeds, LS2 9JT, UK  
 
Corresponding author: Beatrice Bretherton, B.E.Bretherton@leeds.ac.uk 
 
First draft submitted: 17 September 2019; Accepted for publication: 24 September 2019; Published 
online: TBC 
 
Key words: Transcutaneous vagal nerve stimulation; Aging; Autonomic nervous system 
 
14.9 million people in the UK were over 60 years old in 2014, with estimates projected to increase to 
21.9 million people by 2039 [1]. Within this total, the number of individuals aged over 85 years is 
estimated to grow even more に from 1.5 million people aged over 85 years in 2014 reaching 3.6 
million by 2039 [1]. Iデ ｷゲ ﾐﾗデ ﾗﾐﾉ┞ デｴW UK ┘ｴﾗ ｴ;ゲ ;ﾐ ;ｪｷﾐｪ ヮﾗヮ┌ﾉ;デｷﾗﾐぎ デｴW ヮヴﾗヮﾗヴデｷﾗﾐ ﾗa デｴW ┘ﾗヴﾉSげゲ 
population aged over 60 years is expected to increase from 12% in 2015 to 22% by 2050 [2]. Such 
aging populations result from increased life expectancy, bringing individuals and their families 
opportunities unavailable 20-30 years ago. Similarly, the greater life expectancies anticipated in the 
next 30 years will provide new and different opportunities than the ones of today. For individuals to 
make the most of their longer lives, good health is essential, especially for maintaining 
independence and playing an active role in family and community life. However, a challenge to 
prolonging good health is associated with changes in autonomic nervous system function, 
characterized by shifts towards sympathetic and away from parasympathetic prevalence [3]. This 
resulting imbalance in autonomic function can be detrimental to heart function, gut function, 
emotion, mood and quality of life, playing a significant part in the development of age-related 
conditions, such as heart failure [4], hypertension [5] and depression [6]. To treat these conditions, 
pharmacological therapies are typically used, some of which have limited effectiveness, are 
associated with side-effects and lead to a population-wide dependence on medications. Therefore, 
there is an urgent need to find a way that allows people to lead healthy older lives whilst avoiding 
the use of pharmacological and invasive therapies. Stimulating the vagus nerve without surgery may 
be one way of achieving this. 
The vagus nerve, originating in the brainstem, supplies many organs in the body, therefore making it 
a single therapeutic target with potentially widespread effects. It is a main source of the 
parasympathetic branch of the autonomic nervous system, which seeks to maintain homeostasis 
within the body but is also critically important in sensory signaling. Traditionally, stimulation of the 
vagus nerve (VNS), by surgically implanting a generator unit and administering electrical impulses to 
the left cervical vagus, has been used to treat refractory epilepsy and treatment resistant 
depression. However, as surgery is necessary and side-effects have been reported [7], the viability of 
using this form of VNS to prolong the period of healthy aging is unclear.  
Fortunately, the vagus nerve has a small sensory distribution at the cutaneous ear through the 
auricular branch of the vagus nerve (ABVN) [8]. The ABVN can be stimulated non-invasively by 
applying small, pain-aヴWW WﾉWIデヴｷI;ﾉ ｷﾏヮ┌ﾉゲWゲ ふｷくWく ヮ┌ﾉゲW ┘ｷSデｴ ;ヴﾗ┌ﾐS ヲヰヰ ´ゲが aヴWケ┌WﾐI┞ ;ヴﾗ┌ﾐS ンヰ H┣ 
and current 2-4 mA) to specific auricular dermatomes thought to be innervated by the ABVN (usually 
the tragus, concha or cymba concha). This transcutaneous VNS (tVNS) is relatively inexpensive: just 
the cost of a transcutaneous electrical nerve stimulator (TENS) machine and modified auricular 
electrodes to attach the TENS to the ear. More importantly, it is simple to administer, enabling 
individuals to administer it themselves, in their own homes; a major advantage considering the 
mobility and physical challenges that occur with older age. 
Research exploring how tVNS impacts the physiological health of individuals is beginning to show 
that it could have positive effects for aging populations. A single 15-minute session of tVNS, albeit in 
young healthy volunteers, significantly reduced sympathetic nerve activity [9] and improved 
measures of vagal tone [10]. Interestingly, the most pronounced improvements in autonomic 
balance occurred in individuals who had higher sympathetic prevalence at baseline [9], suggesting 
that tVNS may be of particular benefit for older individuals who show this autonomic imbalance. 
Interestingly, a single 15-minute session of tVNS in healthy volunteers aged д 55 years was also 
associated with improvements in autonomic function [11]. These improvements appeared to be 
distinct from autonomic changes associated with sham stimulation (machine turned off without 
participant knowledge): tVNS was associated with greater increases in baroreceptor reflex sensitivity 
[11] and lower sympathetic prevalence compared to sham [9]. In addition, when administered for 15 
minutes every day for two weeks, tVNS improved measures of autonomic function, with response to 
tVNS becoming more pronounced after the two-week period [11].  
As well as benefitting healthy older individuals, tVNS holds potential for patients with age-related 
conditions. For instance, ABVN stimulation for 15 minutes every day for two weeks in individuals 
with coronary artery disease improved exercise tolerance and reliance on vasodilator medication 
[12]. There is also evidence that tVNS has anti-inflammatory effects; an important quality given that 
pro-inflammatory mechanisms strengthen with aging. For instance, in individuals with paroxysmal 
;デヴｷ;ﾉ aｷHヴｷﾉﾉ;デｷﾗﾐが デVNS ゲｷｪﾐｷaｷI;ﾐデﾉ┞ ヴWS┌IWS ヮﾉ;ゲﾏ; ﾉW┗Wﾉゲ ﾗa TNFüが ; ヮヴﾗ-inflammatory cytokine, 
along with atrial fibrillation [13]. In addition, inflammatory responses in the left ventricle of a rat 
model of heart failure were significantly reduced after 4 weeks of tVNS [14]. Therefore, age-related 
conditions characterized by chronic inflammation may be important targets for future tVNS trials. 
Potential conditions include heart failure with reduced ejection fraction, diabetes, hypertension, 
irritable bowel syndromes and chronic pain conditions. Furthermore, due to increasing interest in 
and limited effective treatments for heart failure with preserved ejection fraction (HFpEF), tVNS 
could be a potential treatment modality. Of course, careful consideration should be made of control 
groups and control arms. This is because the perceptible quality of tVNS and controversy in the 
literature about which nerves actually innervate the auricular dermatome make it difficult to 
determine a valid control and to implement double-blinding. 
As well as having positive effects on physiological health, there is increasing support for the role 
tVNS could play in enhancing psychological well-being. Two weeks of daily tVNS in healthy older 
individuals significantly improved aspects of mood, including depression, tension and vigor [11]. The 
effects on depression may be far-reaching: tVNS applied for two weeks [15] and one month [16] in 
patients with depression significantly reduced depression scores. These findings are noteworthy 
given the prevalence of depression, and other mood disorders (e.g. anxiety), in the older age-groups. 
Deteriorations in cognitive ability are also a common feature in the aging process. Fortunately, tVNS 
has been shown to enhance associative memory in older individuals [17], the recognition of 
emotions [18] and divergent thinking [19]. Together these findings provide increasing support for 
using tVNS to combat some of the age-related changes in psychological and cognitive impairments. 
Indeed, it would be prudent to explore the ｷﾏヮ;Iデ ﾗa デVNS ｷﾐ Aﾉ┣ｴWｷﾏWヴげゲ DｷゲWase, particularly for 
individuals who are experiencing the initial stages of memory loss.  
As individuals age, they are often caught in the throes of deteriorating sleep quality. Since sleep 
plays such an important role in health, mood and cognitive function, it could be a key target for 
tVNS. Our recent evidence suggests that aspects of sleep can be improved with tVNS: for individuals 
who had low sleep quality and difficulties falling asleep and waking up, two weeks of daily tVNS was 
associated with improvements [11].  
In conclusion, research clearly shows that tVNS has considerable potential to positively impact aging 
populations. Use of tVNS could delay the progression of age-related conditions for older individuals 
who want to maintain their good health, thereby prolonging the period of healthy aging. 
Additionally, for those who have underlying age-related health conditions (e.g. diabetes, 
hypertension, depression, anxiety, insomnia etc.), tVNS could aid with symptom management, 
thereby reducing the severity of their symptoms, and reliance on medications and healthcare 
utilization. In turn, this could enable older populations to live a healthier longer life that maximizes 
their independence, enabling them to engage with opportunities that are presented to them. 
Positive effects on wider society and the healthcare system could also be realized. With further 
research, the diversity of age-related conditions tVNS can help and the role it can play in healthy 
aging will be realized. 
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